Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

Liver cancer remains a global health challenge, with an estimated incidence of> 1 million
cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer …

There is a continuing debate about the proportion of cancer patients that benefit from
precision oncology, attributable in part to conflicting views as to which molecular alterations …

Molecular imaging has experienced enormous advancements in the areas of imaging
technology, imaging probe and contrast development, and data quality, as well as machine …

Cancer progression is driven in part by genomic alterations. The genomic characterization of
cancers has shown interpatient heterogeneity regarding driver alterations, leading to the …

The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

The development of immune checkpoint inhibitors has changed the treatment paradigm for
advanced cancers across many tumor types. Despite encouraging and sometimes durable …

Metastatic cancer is a major cause of death and is associated with poor treatment efficacy. A
better understanding of the characteristics of late-stage cancer is required to help adapt …

Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are
found in a wide range of cancers. Preclinical modelling suggests that a subset of these …

Improvements in the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC)
have lagged behind advances made in the treatment of many other malignancies over the …